CD274 and neoplasm: However, when we made detailed subgroup analyses of the data from patients aging more than 65, we found there were no differences as to the subgroups of using immune therapy alone, the immune target being PD-L1, tumor stage IIIB or IV, the using in the subsequent line of therapy.